Anti-GARP protein

Patent metadata

Field	Value
Publication number	US-11230603-B2
Application number	US-202016791937-A
Country	US
Kind code	B2
Filing date	Feb 14, 2020
Priority date	Aug 1, 2013
Publication date	Jan 25, 2022
Grant date	Jan 25, 2022

Abstract

The present invention relates to a protein binding to GARP in the presence of TGF-β and uses thereof.

First claim

The invention claimed is:

1. An anti-human Glycoprotein A repetitions predominant (hGARP) antibody, comprising
a heavy chain variable region comprising the following CDRs:

VH-CDR1:

(SEQ ID NO: 52)

GYGIN; 

VH-CDR2:

(SEQ ID NO: 3)

MIWSDGSTDYNSVLTS; and

VH-CDR3:

(SEQ ID NO: 4)

DRNYYDYDGAMDY.

a light chain variable region comprising the following CDRs:

VL-CDR1:

(SEQ ID NO: 5)

KASDHIKNWLA;

VL-CDR2:

(SEQ ID NO: 6)

GATSLEA;

and

VL-CDR3:

(SEQ ID NO: 7)

QQYWSTPWT.

2. An antibody or antigen binding fragment produced by a hybridoma registered under the accession number LMBP 10246CB on May 30, 2013.

3. A hybridoma cell line producing an antibody against GARP registered under the accession number LMBP 10246CB on May 30, 2013.

4. A polynucleotide sequence encoding the antibody molecule of claim 1 .

5. An expression vector comprising the polynucleotide sequence of claim 4 .

6. An isolated host cell comprising the vector of claim 5 .

7. A method of producing an anti-hGARP antibody, comprising culturing the host cell of claim 6 under conditions to express the antibody, and recovering the expressed antibody.

8. The antibody of claim 1 , which is labeled with a detectable label, wherein the detectable label comprises at least one element, isotope, or chemical compound attached to the antibody to enable detection.

9. A kit comprising the antibody of claim 1 , wherein the kit is used to identify the presence of a complex of hGARP and latent TGF-β1 in a biological sample.

10. A kit comprising the antibody of claim 1 , wherein the kit is used to identify activated Tregs in a biological sample.

11. The anti-hGARP antibody of claim 1 , wherein the heavy chain variable region comprises a VH-CDR1 having the amino acid sequence of GFSLTGYGIN (SEQ ID NO:2).

12. The anti-hGARP antibody of claim 1 , wherein the antibody is a humanized antibody.

13. The antibody of claim 12 , which is an IgG1 or IgG4 antibody.

14. The anti-hGARP antibody of claim 11 , comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:50, and a light chain variable region having the amino acid sequence of SEQ ID NO:51.

15. The anti-hGARP antibody of claim 11 , comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:8, and a light chain variable region having the amino acid sequence of SEQ ID NO:9.

Assignees

• Ludwig Inst For Cancer Res Ltd
• Univ Catholique Louvain
• Argenx Bvba

Inventors

• Lucas Sophie
• Coulie Pierre
• Cuende Villasur Julia
• Dumoutier Laure
• Renauld Jean-Christophe
• Van Der Woning Sebastian
• Saunders Michael
• De Haard Hans
• De Boeck Gitte

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title